Compare iShares MSCI Australia ETF (EWA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI Australia ETF trades at $29.94, while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: iShares MSCI Australia ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EWA | RXRX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.41 | $6.79 |
52-Week Low | $24.95 | $2.84 |
Market Cap | — | $1.78B |
Enterprise Value | — | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $30.41, up 0.83% with a bullish technical bias from moving averages, though oscillators signal caution with RSI levels above 70 indicating potential overbought conditions. The stock shows strong momentum with ADX readings above 36, while support and resistance cluster near $30-$31. Recent corporate actions include a scheduled dividend of $0.40 per share for June 2026.
Outlook remains positive given technical strength, but elevated RSI warrants monitoring for pullbacks. Risks include macroeconomic sensitivity and sector competition. Investment appeal hinges on sustained earnings growth and dividend stability, with current levels offering limited upside near resistance.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
